Organisation: Novo Nordisk AS

Danish pharmaceutical group Novo Nordisk is preparing to launch an ICC arbitration worth US$830 million against a Singapore biosciences company for alleged fraud, after acquiring a hypertension drug that failed in clinical trials. 

19 February 2025